MedTrace Logo

Losartan for Corneal Fibrosis

NCT07449000 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2026-05-08

No results posted yet for this study

Summary

This is a prospective, randomized, double-blinded, controlled clinical trial designed to evaluate the efficacy and safety of topical losartan in improving visual acuity, contrast sensitivity and reducing corneal densitometry, corneal aberrations and corneal scarring severity in adult patients with corneal scars of different etiologies. Participants will be randomly assigned to receive either topical losartan 0.8 mg/mL or placebo eyedrops 6 times per day for six months.

Conditions

  • Corneal Scarring Fibrosis

Interventions

DRUG

Topical losartan

Drug: Topical Losartan 0.8 mg/ml ophthalmic solution, one drop applied six times daily for six months.

DRUG

Placebo Control

Drug: Balanced saline solution ophthalmic drops, one drop applied six times daily for six months.

Sponsors & Collaborators

  • Universidad Autonoma de Nuevo Leon

    lead OTHER

Principal Investigators

  • Karim Mohamed-Noriega, Dr. med. · Universidad Autonoma de Nuevo Leon

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-12
Primary Completion
2027-02-11
Completion
2027-03-01

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07449000 on ClinicalTrials.gov